Healthcare · Biotechnology
Price
$0.89
Market Cap
$49.7M
Employees
24
Beta
1.56
Avg Volume
1,044,077
CEO
Frank K. Bedu-Addo
Business Description
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.20
Stock Price: $0.89
EPS (Diluted): -0.74
EPS (Diluted): -0.74
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.86
Stock Price: $0.89
Total Equity: $9.25M
Shares: 46,384,280
Total Equity: $9.25M
Shares: 46,384,280
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.57
Market Cap: $49.74M
Total Debt: $16.86M
Cash: $26.71M
EBITDA: -$30.30M
Total Debt: $16.86M
Cash: $26.71M
EBITDA: -$30.30M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$25.9M
Market Cap: $49.74M
Total Debt: $16.86M
Cash: $26.71M
Total Debt: $16.86M
Cash: $26.71M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.89
Revenue: $0.00
Shares: 46,384,280
Revenue: $0.00
Shares: 46,384,280
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$31.54M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$34.50M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-346.0%
Net Income: -$34.50M
Total Equity: $9.25M
Total Equity: $9.25M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-146.6%
Operating Income: -$31.54M
Tax Rate: 3.3%
Equity: $9.25M
Total Debt: $16.86M
Cash: $26.71M
Tax Rate: 3.3%
Equity: $9.25M
Total Debt: $16.86M
Cash: $26.71M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.98
Current Assets: $28.25M
Current Liabilities: $9.48M
Current Liabilities: $9.48M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
1.82
Short-Term Debt: $5.13M
Long-Term Debt: $11.73M
Total Debt: $16.86M
Total Equity: $9.25M
Long-Term Debt: $11.73M
Total Debt: $16.86M
Total Equity: $9.25M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 46,384,280
Shares: 46,384,280
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.20
Total Equity: $9.25M
Shares: 46,384,280
Shares: 46,384,280
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-598.31
Operating CF: -$27.75B
CapEx: $0.00
Shares: 46,384,280
CapEx: $0.00
Shares: 46,384,280
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.89
Stock Price: $0.89
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$34.50M
Net Income: -$34.50M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PDSB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 10:33am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $57,326 | $59,791 | $0 |
| Gross Profit | $0 | $0 | $-57,326 | $-59,791 | $0 |
| Operating Expenses | $21.4M | $41.7M | $43.0M | $36.3M | $31.5M |
| Operating Income | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| Net Income | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| EBITDA | -$21.4M | -$40.7M | -$40.1M | -$33.7M | -$30.3M |
| EPS | $-0.66 | $-1.43 | $-1.39 | $-1.03 | $-0.74 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 10:33am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $65.2M | $73.8M | $56.6M | $41.7M | $26.7M |
| Total Current Assets | $66.8M | $76.5M | $59.1M | $45.1M | $28.3M |
| Total Assets | $67.2M | $77.0M | $59.4M | $45.4M | $30.5M |
| Current Liabilities | $3.8M | $9.8M | $13.6M | $17.1M | $9.5M |
| Long-Term Debt | $0 | $23.0M | $19.5M | $9.2M | $11.7M |
| Total Liabilities | $4.0M | $33.0M | $33.3M | $26.4M | $21.2M |
| Total Equity | $63.2M | $44.0M | $26.1M | $19.0M | $9.3M |
| Retained Earnings | -$60.7M | -$101.6M | -$144.5M | -$182.1M | -$216.6M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 10:33am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.5M | -$25.7M | -$33.6M | -$35.0M | -$27.8B |
| Capital Expenditure | $0 | $0 | $0 | $-29,000 | $0 |
| Free Cash Flow | -$12.5M | -$25.7M | -$33.6M | -$35.1M | -$27.8B |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $36.4M | $8.6M | -$17.3M | -$14.9M | -$15.0B |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:35am (22h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$23.2M $23.2M – $23.2M
|
$3.8M $3.8M – $3.8M
|
$93.4M $93.4M – $93.4M
|
$196.9M $196.9M – $196.9M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$21.6M -$26.4M – -$16.9M
|
-$19.5M -$22.7M – -$16.2M
|
$23.2M $23.2M – $23.2M
|
$70.0M $70.0M – $70.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 10:33am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | -4.3% | +100.0% |
| Operating Income Growth | -94.4% | -3.3% | +15.6% | +13.2% |
| Net Income Growth | -141.5% | -5.1% | +12.4% | +8.3% |
| EBITDA Growth | -90.1% | +1.6% | +15.8% | +10.2% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:48am (3h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-01-12 | BEDU-ADDO FRANK | A-Award | 548,782.00 | $0.98 | $537,806 |
| 2026-01-12 | CONN GREGORY | A-Award | 150,000.00 | $0.98 | $147,000 |
| 2026-01-12 | Shepard Kirk V. | A-Award | 300,000.00 | $0.98 | $294,000 |
| 2026-01-12 | Boesgaard Lars | A-Award | 300,000.00 | $0.98 | $294,000 |
| 2026-01-12 | Brown Spencer D. | A-Award | 300,000.00 | $0.98 | $294,000 |
| 2026-01-12 | Toutain Stephan | A-Award | 300,000.00 | $0.98 | $294,000 |
| 2026-01-12 | Freitag Gregory Gene | A-Award | 54,876.00 | $0.98 | $53,778 |
| 2026-01-12 | Iliev Ilian | A-Award | 54,876.00 | $0.98 | $53,778 |
| 2026-01-12 | Ali-Jackson Kamil | A-Award | 54,876.00 | $0.98 | $53,778 |
| 2026-01-12 | BRAWLEY OTIS W | A-Award | 54,876.00 | $0.98 | $53,778 |
| 2026-01-12 | Glover Stephen C. | A-Award | 54,876.00 | $0.98 | $53,778 |
| 2024-02-28 | BEDU-ADDO FRANK | A-Award | 300,000.00 | $5.87 | $1.8M |
| 2025-06-12 | BEDU-ADDO FRANK | A-Award | 150,000.00 | $1.79 | $268,500 |
| 2025-06-12 | Shepard Kirk V. | A-Award | 150,000.00 | $1.79 | $268,500 |
| 2025-06-12 | Brown Spencer D. | A-Award | 150,000.00 | $1.79 | $268,500 |
| 2024-02-28 | Brown Spencer D. | A-Award | 56,000.00 | $5.87 | $328,720 |
| 2025-06-12 | Boesgaard Lars | A-Award | 150,000.00 | $1.79 | $268,500 |
| 2024-02-28 | CONN GREGORY | A-Award | 46,648.00 | $5.87 | $273,824 |
| 2025-06-12 | CONN GREGORY | A-Award | 40,000.00 | $1.79 | $71,600 |
| 2025-06-12 | Toutain Stephan | A-Award | 150,000.00 | $1.79 | $268,500 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PDSB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for PDSB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30